AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2906863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention with reinforcement and aversive consequences
Number of subjects: 16
Study 2906863 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention with aversive consequences
Number of subjects: 16
Study 5098326 — intervention group
Group type: EXPERIMENTAL
Intervention: bean-containing, high crude-fibre diet
Number of subjects: 10
Study 5098326 — intervention group
Group type: COMPARATOR
Intervention: restricted crude-fibre content diet
Number of subjects: 10
Study 5098326 — intervention group
Group type: COMPARATOR
Intervention: liquid chemically defined diet
Number of subjects: 10
Study 31762105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (integrating smoking cessation treatment into usual AOD treatment)
Number of subjects: 896
Study 31762105 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 896
Study 31629118 — intervention group
Group type: EXPERIMENTAL
Intervention: Telelactation
Number of subjects: 203
Study 31629118 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study 28728986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular total thyroid enucleation (ITTE)
Number of subjects: 224
Study 28728986 — intervention group
Group type: COMPARATOR
Intervention: Standard total thyroidectomy (STT)
Number of subjects: 224
Study 26489030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention and diabetes support and education
Number of subjects: 2118
Study 26489030 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 2118
Study 23405021 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-chosen activity group (n = 30)
Number of subjects: 59
Study 23405021 — intervention group
Group type: COMPARATOR
Intervention: Therapist-chosen activity group (n = 29)
Number of subjects: 59
Study 21778171 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus up to 12 sessions of individual rumination-focused CBT
Number of subjects: 42
Study 21778171 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study 19745765 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab (F, CP-751,871) 0.05-20 mg/kg in combination with paclitaxel 200 mg/m2 and carboplatin (AUC 6) q3 weeks for up to six cycles.
Number of subjects: 42
Study 19745765 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab (F, CP-751,871) 10 and 20 mg/kg dosing cohorts.
Number of subjects: 42
Study 19745765 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 42
Study 16390351 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL)
Number of subjects: 36
Study 16390351 — intervention group
Group type: COMPARATOR
Intervention: Water (300 mL)
Number of subjects: 36
Study 15327643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine mouthrinse
Number of subjects: 0
Study 15327643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine mouthrinse
Number of subjects: 0
Study 15327643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 0
Study 15327643 — intervention group
Group type: COMPARATOR
Intervention: Control rinse (without chlorhexidine)
Number of subjects: 0
Study 11174009 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (112 +/- 7 mg/day)
Number of subjects: 28
Study 11174009 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8 +/- 1 mg/day)
Number of subjects: 28
Study 11174009 — intervention group
Group type: COMPARATOR
Intervention: Captopril and Doxazosin (comparison)
Number of subjects: 28
Study 9059480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol during CPAP via face mask
Number of subjects: 9
Study 9059480 — intervention group
Group type: COMPARATOR
Intervention: Conventional nebulisation (control)
Number of subjects: 9
Study 9059480 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O at a FGF rate of 50 l/min
Number of subjects: 9
Study 8299431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (d‐alpha‐tocopherol; 900 mg/day)
Number of subjects: 25
Study 3088266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40
Study 3088266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30087378 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated approach with automated detection of alveolar ridges (RapidNAM)
Number of subjects: 2
Study 30087378 — intervention group
Group type: COMPARATOR
Intervention: Conventional CAD/CAM-intraoral molding (stepwise manual design)
Number of subjects: 2
Study 27040132 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg per day
Number of subjects: 12705
Study 27040132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12705
Study 25159546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track care program (n = 40)
Number of subjects: 76
Study 25159546 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care protocol (control group, n = 36)
Number of subjects: 76
Study 21923981 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts
Number of subjects: 64
Study 21923981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20861207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of LDL levels
Number of subjects: 221
Study 20861207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of HDL levels
Number of subjects: 221
Study 20861207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of TG levels
Number of subjects: 221
Study 20861207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of Lpa levels
Number of subjects: 221
Study 20861207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of homocysteine levels
Number of subjects: 221
Study 20861207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of hs-CRP levels
Number of subjects: 221
Study 18271912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (fixed dose of 50 mg or 200 mg daily in Study 1; flexible dose of 100‐400 mg daily in Study 2; fixed dose of 200 mg daily in Studies 3, 4 and 5)
Number of subjects: 0
Study 18271912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16163899 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Iclopid tablets (test formulation)
Number of subjects: 0
Study 16163899 — intervention group
Group type: COMPARATOR
Intervention: 250 mg Ticlid tablets (reference formulation)
Number of subjects: 0
Study 14585916 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2-specific inhibitors (celecoxib or valdecoxib)
Number of subjects: 0
Study 14585916 — intervention group
Group type: COMPARATOR
Intervention: Non-specific NSAIDs
Number of subjects: 0
Study 11789208 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenjian granule (ZJG)
Number of subjects: 52
Study 11789208 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 52
Study 8892495 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive frame
Number of subjects: 292
Study 8892495 — intervention group
Group type: COMPARATOR
Intervention: Negative frame
Number of subjects: 292
Study 1354367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichromats
Number of subjects: 7
Study 1354367 — intervention group
Group type: COMPARATOR
Intervention: Trichromats
Number of subjects: 7
Study 6327600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pivmecillinam for up to three months
Number of subjects: 44
Study 6327600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study 30903341 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful revascularization (74%) in patients with FVH–DWI mismatch (80% success rate, 63/79 patients)
Number of subjects: 100
Study 30903341 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable outcome (modified Rankin Scale score ≤ 2) for revascularization in patients with FVH–DWI mismatch
Number of subjects: 100
Study 30903341 — intervention group
Group type: COMPARATOR
Intervention: Favorable outcome (modified Rankin Scale score ≤ 2) for revascularization in patients without FVH–DWI mismatch
Number of subjects: 100
Study 30903341 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable outcome after adjustment for NIHSS in patients with FVH–DWI mismatch
Number of subjects: 100
Study 30903341 — intervention group
Group type: COMPARATOR
Intervention: Favorable outcome after adjustment for NIHSS in patients without FVH–DWI mismatch
Number of subjects: 100
Study 30903341 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable outcome after adjustment for DWI volume in patients with FVH–DWI mismatch
Number of subjects: 100
Study 30903341 — intervention group
Group type: COMPARATOR
Intervention: Favorable outcome after adjustment for DWI volume in patients without FVH–DWI mismatch
Number of subjects: 100
Study 30290983 — intervention group
Group type: COMPARATOR
Intervention: Commercial ultrasound transmission gel (USTG)
Number of subjects: 193
Study 30290983 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan gel
Number of subjects: 193
Study 27801405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TMS (rTMS) at a frequency of 10 Hz
Number of subjects: 22
Study 27801405 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta bursts stimulation (iTBS)
Number of subjects: 22
Study 27801405 — intervention group
Group type: COMPARATOR
Intervention: Both rTMS and iTBS
Number of subjects: 22
Study 24813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d (days 1-21)
Number of subjects: 135
Study 24813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg/d (days 1-28)
Number of subjects: 135
Study 24813620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 24813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d
Number of subjects: 135
Study 24813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg/d
Number of subjects: 135
Study 24813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-treated patients with RBC-TI ≥182 d
Number of subjects: 135
Study 24813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 135
Study 21988705 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera/olive oil cream
Number of subjects: 67
Study 21988705 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 0.1% cream
Number of subjects: 67
Study 20152239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract plus supplement
Number of subjects: 60
Study 20152239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18818191 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PPF)
Number of subjects: 34
Study 18818191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 34
Study 18818191 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 34
Study 18818191 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 34
Study 15707855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 100 mg once daily for 72 hours
Number of subjects: 47
Study 15707855 — intervention group
Group type: COMPARATOR
Intervention: IV hydrocortisone 100 mg every 6 hours for 72 hours
Number of subjects: 47
Study 12608488 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.836 g/kg)
Number of subjects: 16
Study 12608488 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (control)
Number of subjects: 16
Study 10701468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 387
Study 10701468 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 387
Study 7852497 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin D (25OHD; 20 micrograms/day for approximately 34 days)
Number of subjects: 41
Study 7852497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment with 25OHD)
Number of subjects: 41
Study 1719708 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 207
Study 1719708 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 207
Study 7284649 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg per day for two weeks
Number of subjects: 0
Study 7284649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30744149 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon with mashed potatoes (high GI)
Number of subjects: 25
Study 30744149 — intervention group
Group type: COMPARATOR
Intervention: Salmon with wholegrain pasta (low GI)
Number of subjects: 25
Study 30744149 — intervention group
Group type: COMPARATOR
Intervention: Veal with mashed potatoes (high GI)
Number of subjects: 25
Study 30744149 — intervention group
Group type: COMPARATOR
Intervention: Veal with wholegrain pasta (low GI)
Number of subjects: 25
Study 27836430 — intervention group
Group type: COMPARATOR
Intervention: Monthly dosing with ranibizumab 0.3 mg every 4 weeks
Number of subjects: 150
Study 27836430 — intervention group
Group type: EXPERIMENTAL
Intervention: TReat and EXtend without macular laser photocoagulation (TREX)
Number of subjects: 150
Study 27836430 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat and extend with angiography‐Guided macular Laser photocoagulation (GILA)
Number of subjects: 150
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual study diameter (SDM) using RECIST
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective diameter (EDM)
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM change rate (SDM-CR)
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: EDM change rate (EDM-CR)
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM-CR variability
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: EDM-CR variability
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated RECIST diameter (aRDM)
Number of subjects: 14
Study 25778472 — intervention group
Group type: EXPERIMENTAL
Intervention: EDM change significance
Number of subjects: 14
Study 23142625 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 165
Study 20473670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing system
Number of subjects: 0
Study 20473670 — intervention group
Group type: COMPARATOR
Intervention: Conventional prosthesis
Number of subjects: 0
Study 20473670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 19372356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound needle end point
Number of subjects: 81
Study 19372356 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation needle end point
Number of subjects: 81
Study 17291319 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial optimism about achieving a 'normal life' after diagnosis
Number of subjects: 32
Study 17291319 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of normality over time
Number of subjects: 32
Study 17291319 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment to new normal
Number of subjects: 32
Study 15580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 15580211 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 12971817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed training with concurrent production and sound identification training
Number of subjects: 9
Study 12971817 — intervention group
Group type: COMPARATOR
Intervention: Production-only training
Number of subjects: 9
Study 10658511 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuo-spatial working memory tasks with additional load of retaining and recalling target appearance
Number of subjects: 0
Study 10658511 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuo-spatial working memory tasks with articulatory suppression
Number of subjects: 0
Study 7493457 — intervention group
Group type: EXPERIMENTAL
Intervention: NiSO4 0.1 M + MgSO4 0.1 M, 0.3 M, 0.5 M
Number of subjects: 110
Study 7493457 — intervention group
Group type: EXPERIMENTAL
Intervention: NiCl2 0.1 M + MgCl2 0.3 M, 0.5 M, 1 M
Number of subjects: 110
Study 7493457 — intervention group
Group type: COMPARATOR
Intervention: NiSO4 0.1 M, NiCl2 0.1 M, Na2SO4 0.3 M, NaCl 0.3 M
Number of subjects: 110
Study 2088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Romazarit (single oral doses ranging from 40 to 1500 mg)
Number of subjects: 44
Study 2088768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsules)
Number of subjects: 44
Study 400313 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate 0.1%
Number of subjects: 0
Study 400313 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1%
Number of subjects: 0
Study 400313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30027751 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from origin to insertion (n=7)
Number of subjects: 15
Study 30027751 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from insertion to origin (n=8)
Number of subjects: 15
Study 30027751 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied in the opposite direction after 1 week (insertion to origin [n=7] or origin to insertion [n=8])
Number of subjects: 15
Study 30027751 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape application (both directions)
Number of subjects: 15
Study 28644761 — intervention group
Group type: EXPERIMENTAL
Intervention: Satir communication family therapy (CFT), 7 sessions
Number of subjects: 53
Study 28644761 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 53
Study 26489663 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive ketamine
Number of subjects: 100
Study 26489663 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 23435190 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (0.5% AR-12286 Ophthalmic Solution) once daily, both eyes for 8 days
Number of subjects: 18
Study 23435190 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (0.5% AR-12286 Ophthalmic Solution) once daily, both eyes for 8 days
Number of subjects: 18
Study 21349260 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg
Number of subjects: 0
Study 21349260 — intervention group
Group type: COMPARATOR
Intervention: statin monotherapy (baseline)
Number of subjects: 0
Study 19709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread breakfast with bran
Number of subjects: 32
Study 19709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread breakfast with intermediate fraction (B4)
Number of subjects: 32
Study 19709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread breakfast with sifted flour
Number of subjects: 32
Study 19709412 — intervention group
Group type: COMPARATOR
Intervention: Wheat reference bread breakfast
Number of subjects: 32
Study 19709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran (5g and 8g)
Number of subjects: 32
Study 19709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate rye fraction (5g and 8g)
Number of subjects: 32
Study 17627241 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 9 mg/kg dose antithymocyte globulin (ATG)
Number of subjects: 155
Study 17627241 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 20 mg doses of basiliximab
Number of subjects: 155
Study 17627241 — intervention group
Group type: COMPARATOR
Intervention: Conventional CsA triple therapy without induction
Number of subjects: 155
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) using Siri's equation (%FM(ADP-Siri))
Number of subjects: 34
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) using predicted lung volume
Number of subjects: 34
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) using measured lung volume
Number of subjects: 34
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP)
Number of subjects: 34
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) in children <35 kg
Number of subjects: 34
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) in girls
Number of subjects: 34
Study 15128913 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) in boys
Number of subjects: 34
Study 11876141 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 3
Study 11876141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 11876141 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 3
Study 11876141 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 3
Study 9717593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg i.v.)
Number of subjects: 40
Study 9717593 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms i.v.)
Number of subjects: 40
Study 9717593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40
Study 9717593 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study 31857535 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients (intervention group)
Number of subjects: 51
Study 31857535 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 51
Study 29178702 — intervention group
Group type: EXPERIMENTAL
Intervention: resin‐modified glass ionomer varnish ‐ Clinpro XT Varnish
Number of subjects: 30